Verition Fund Management’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-40,000
Closed -$2.41M – 2392
2026
Q2
$2.41M Sell
40,000
-15,000
-27% -$833K 0.01% 1013
2026
Q1
$3.2M Sell
55,000
-38,756
-41% -$1.79M 0.02% 769
2025
Q4
$4.2M Buy
93,756
+36,639
+64% +$1.54M 0.02% 1006
2025
Q3
$2.29M Buy
+57,117
New +$2.01M 0.01% 1856
2025
Q2
– Sell
-12,508
Closed -$420K – 3904
2025
Q1
$420K Buy
12,508
+4,211
+51% +$160K ﹤0.01% 2689
2024
Q4
$325K Buy
+8,297
New +$343K ﹤0.01% 2739

Other funds holding XENE

Verition Fund Management's XENE Position: Q3 2026 in Review

Verition Fund Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2026, closing a stake of 40,000 shares — an estimated $2.41M sold.

Verition Fund Management first reported a position in XENE in Q4 2024 and held it in 6 quarters. The position peaked at $4.2M in Q4 2025. 286 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Verition Fund Management reported no remaining Xenon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Verition Fund Management sold 40,000 Xenon Pharmaceuticals shares in Q3 2026, an estimated $2.41M.
  • Verition Fund Management first reported a position in Xenon Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Verition Fund Management's Xenon Pharmaceuticals position peaked at $4.2M in Q4 2025.
  • 286 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.